Table 3.

Genotypic Resistance Profiles, Pretreatment and Posttreatment by Antiretroviral Regimen, Lopinavir/Ritonavir-Based (LPV/r) Compared with Ritonavir-Based (RTV-Based), of 41 Children Who Were Not Virologically Suppressed

Number	Pretreatment PI	Pretreatment NNRTI	Pretreatment NRTI	Endpoint PI	Endpoint NNRTI	Endpoint NRTI
Maintained on LPV/r-based regimen throughout study period
1						M184V
2		K103N			K103N	M184V
3						M184V
4						M184V
5						K70E
6
7
8				(protease did not amplify)
Received RTV-based regimen during study period
9		K103N, Y188C		I54V, V82A		M184V
10		Y181C	K219E	V82A, L90M		M184V
11		Y181C		V82A		M184I
12				V82A		M184V
13				V82A		M184V
14				V82A		M184V
15		Y181C		L10F, M46I, I54V, V82A		M184V
16		Y181C	K219E	L10F, M46I, I54V, V82A		M184V
17		V179D		M46I, F53L, I54V, V82A		D67N, M184V
18				M46I, I54V, V82A		A62V, M184V
19		Y181C		L33F, I54V, V82A		M184V
20				L10R, I54V, V82A		A62V, M184V
21	L10I			L10I, V82A		M184V
22				L10F, I54V, Q58E, V82A		D67N, M184V
23		E138A		I54V	E138A	M184V
24				L24I, I54V	E138A	M184V
25				L10V		M184V
26	A71T			A71T
27					Y181C
28		G190A			G190A
29		Y181C				M184V
30						M184V
31						M184V
32						M184V
33						M184V
34				(protease did not amplify)		M184V
35						M184V
36						M184V
37
38
39
40
41

Gray shading, data not available; italics, major mutations maintained from baseline; bold, major mutations defined by 2009 IAS-USA list.